Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
NEEDHAM, Mass., May 07, 2020 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a clinical, late-stage biopharmaceutical company focused on improving the lives of patients who face challenges...
-
NEEDHAM, Mass., April 08, 2020 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a clinical, late-stage biopharmaceutical company focused on improving the lives of patients with rare and serious...
-
MYCAPSSA® PDUFA Date Set for June 26, 2020; U.S. Commercial Launch Planned in Q4’20 First Industry Sponsored U.S. Disease State Registry for Acromegaly Began Enrolling Patients NEEDHAM, Mass.,...
-
NEEDHAM, Mass., March 09, 2020 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic...
-
FDA sets PDUFA date of June 26, 2020 Acceptance follows December 26, 2019 NDA resubmission NEEDHAM, Mass., Jan. 13, 2020 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a clinical-stage...
-
MYCAPSSA® NDA resubmitted to FDA; PDUFA decision expected mid-2020 MYCAPSSA® U.S. commercial launch planned for the fourth quarter of 2020 Top-line MYCAPSSA® MPOWERED Phase 3 results on track for...
-
NEEDHAM, Mass., Dec. 19, 2019 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic...
-
WALTHAM, Mass., Nov. 26, 2019 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic...
-
WALTHAM, Mass., Nov. 14, 2019 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic...
-
CHIASMA OPTIMAL trial, conducted under SPA and designed to support FDA approval, met the primary and all secondary endpoints MYCAPSSA® NDA on track for submission by year-end 2019 MPOWEREDTM Phase 3...